Ching-Lin Hsieh

List of Publications by Year in Descending Order

34 papers	6,711 citations	16 h-index	37 g-index
37 ext. papers	9,114 ext. citations	15.3 avg, IF	6.84 L-index

#	Paper	IF	Citations
34	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.. *EClinicalMedicine*, **2022**, 45, 101323	11.3	4
33	The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes.. *Nature Structural and Molecular Biology*, **2022**,	17.6	6
32	Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins.. *Nature Communications*, **2022**, 13, 1299	17.4	1
31	Protein engineering responses to the COVID-19 pandemic.. *Current Opinion in Structural Biology*, **2022**, 74, 102385	8.1	0
30	Expression and characterization of SARS-CoV-2 spike proteins. *Nature Protocols*, **2021**, 16, 5339-5356	18.8	4
29	Stabilized coronavirus spike stem elicits a broadly protective antibody. *Cell Reports*, **2021**, 37, 109929	10.6	18
28	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines **2021**,		12
27	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. *Nature*, **2021**, 594, 253-258	50.4	92
26	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. *Science Translational Medicine*, **2021**, 13,	17.5	169
25	Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality **2021**,		4
24	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. *Science Immunology*, **2021**, 6,	28	70
23	Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates **2021**,		7
22	Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial **2021**,		5
21	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. *Cell Reports*, **2021**, 37, 109784	10.6	7
20	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. *Cell*, **2021**, 184, 5432-5447.e16	56.2	34
19	Broad neutralization of SARS-related viruses by human monoclonal antibodies. *Science*, **2020**, 369, 731-736	33.3	376
18	Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*, **2020**, 367, 1260-1263	33.3	5176

17	Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein **2020**,		18
16	Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes **2020**,		27
15	LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection **2020**,		64
14	Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science*, **2020**, 369, 1501-1505	33.3	450
13	Comparative screening of recombinant antigen thermostability for improved leptospirosis vaccine design. *Biotechnology and Bioengineering*, **2019**, 116, 260-271	4.9	3
12	Immunoglobulin-Like Protein B Interacts with the 20th Exon of Human Tropoelastin Contributing to Adhesion to Human Lung Cells. *Frontiers in Cellular and Infection Microbiology*, **2017**, 7, 163	5.9	6
11	Extended low-resolution structure of a antigen offers high bactericidal antibody accessibility amenable to vaccine design. *ELife*, **2017**, 6,	8.9	7
10	Leptospira Immunoglobulin-Like Protein B (LigB) Binds to Both the C-Terminal 23 Amino Acids of Fibrinogen □ Domain and Factor XIII: Insight into the Mechanism of LigB-Mediated Blockage of Fibrinogen □Chain Cross-Linking. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004974	4.8	11
9	Fine Mapping of the Interaction between C4b-Binding Protein and Outer Membrane Proteins LigA and LigB of Pathogenic Leptospira interrogans. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0004192	4.8	23
8	NMR solution structure of the terminal immunoglobulin-like domain from the leptospira host-interacting outer membrane protein, LigB. *Biochemistry*, **2014**, 53, 5249-60	3.2	16
7	Elastin, a novel extracellular matrix protein adhering to mycobacterial antigen 85 complex. *Journal of Biological Chemistry*, **2013**, 288, 3886-96	5.4	27
6	The perturbation of tryptophan fluorescence by phenylalanine to alanine mutations identifies the hydrophobic core in a subset of bacterial Ig-like domains. *Biochemistry*, **2013**, 52, 4589-91	3.2	3
5	Dynamics of cleft closure of the GluA2 ligand-binding domain in the presence of full and partial agonists revealed by hydrogen-deuterium exchange. *Journal of Biological Chemistry*, **2013**, 288, 27658-27666	5.4	21
4	Novel mycobacteria antigen 85 complex binding motif on fibronectin. *Journal of Biological Chemistry*, **2012**, 287, 1892-902	5.4	30
3	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition		1
2	The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes		3
1	Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses		14